Dopamine agonist monotherapy in early Parkinson's disease

Research output: Contribution to journalArticle

Authors

Abstract

While levodopa therapy for Parkinson's disease is still considered the gold standard, motor complications are significant disadvantages of treatment. Monotherapy with dopamine agonists may present an alternative approach with a reduced likelihood of developing dyskinesias. Further studies are required before a definitive judgment can be made.

Details

Original languageEnglish
Pages (from-to)8-11
Number of pages4
JournalHospital Medicine
Volume64
Publication statusPublished - 1 Jan 2003